{"id":1803,"date":"2023-02-20T05:51:24","date_gmt":"2023-02-20T05:51:24","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"modified":"2023-03-17T06:20:25","modified_gmt":"2023-03-17T06:20:25","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","title":{"rendered":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study"},"content":{"rendered":"\n<p>SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.<\/p>\n\n\n\n<p>According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, triple-negative breast cancer (\u201cTNBC\u201d) accounted for approximately 15% to 20% of them. TNBC is a more aggressive type of tumor with a higher risk of recurrence and poor prognosis. Advanced TNBC is insensitive to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.<\/p>\n\n\n\n<p>In recent years, oncology immunotherapy drugs represented by PD-(L)1 inhibitors have achieved a series of breakthroughs in treating various types of tumors. However, to this day, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combined chemotherapy have poor efficacy, with a median survival time of about nine to 12 months and a 5-year survival rate of less than 30%.<\/p>\n\n\n\n<p>The TORCHLIGHT study is the first Phase III registration study in China to achieve a positive outcome in an advanced triple-negative breast cancer immunotherapy. This randomized, double-blind, placebo-controlled, multi-center Phase III clinical study was designed to compare the safety and efficacy of toripalimab combined with paclitaxel for injection (albumin-bound) and placebo combined with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV breast cancer or recurrent\/metastatic triple-negative breast cancer.<\/p>\n\n\n\n<p>The interim analysis of this study demonstrated that, compared with paclitaxel for injection (albumin-bound), toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer can significantly prolong the progression-free survival (PFS) of PD-L1 positive patients. Meanwhile, the overall survival (OS), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients regardless of PD-1 status. The safety data of toripalimab is consistent with known risks, and no new safety signals were identified.<\/p>\n\n\n\n<p>\u201cThe TNBC subtype of breast cancer is the most aggressive and has the worst prognosis,\u201d said Professor Zefei JIANG from the Department of Oncology at the Chinese People\u2019s Liberation Army General Hospital, the Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Principal Investigator of the TORCHLIGHT study. \u201cAdvanced TNBC patients have limited survival rates and lack effective treatment methods. Aiming to improve patient survival, a group of Chinese researchers successfully conducted the first phase III study on immune-oncology for advanced TNBC patients, even amidst the COVID-19 pandemic, and achieved breakthrough results. These results demonstrate that the combined use of the monoclonal antibody, toripalimab, with traditional chemotherapy significantly prolonged the PFS of patients, and this has the potential to become a new standard treatment for patients with an initial diagnosis of stage IV TNBC as well as those with recurrent\/metastatic TNBC, offering patients new hope!\u201d<\/p>\n\n\n\n<p>\u201cI\u2019m extremely pleased that TORCHLIGHT research has been successful, and its success is a result of the dedicated efforts of patients, researchers, and development teams,\u201d said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. \u201cWe will work closely with regulatory authorities to ensure that relevant indications are approved as soon as possible. We hope that toripalimab will provide better treatment options for patients and address unmet medical needs.\u201d<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n\n\n\n\n<p><strong>About Toripalimab<\/strong><\/p>\n\n\n\n<p>Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n<p>More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n<p>In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n<ol class=\"wp-block-list\" type=\"1\">\n<li>unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n<li>recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n<li>locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n<li>in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n<li>in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic ESCC;<\/li>\n\n\n\n<li>in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\u201cNSCLC\u201d).<\/li>\n<\/ol>\n\n\n\n<p><\/p>\n\n\n\n<p>The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.<\/p>\n\n\n\n<p>In terms of international layout, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). In December 2022 and February 2023, the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) accepted the marketing authorization application (MAA) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic esophageal squamous cell carcinoma, respectively.<\/p>\n\n\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) &#8212; Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T05:51:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-17T06:20:25+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study\",\"datePublished\":\"2023-02-20T05:51:24+00:00\",\"dateModified\":\"2023-03-17T06:20:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"},\"wordCount\":1100,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\",\"name\":\"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2023-02-20T05:51:24+00:00\",\"dateModified\":\"2023-03-17T06:20:25+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, February 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cTORCHLIGHT Study\u201d, NCT04085276) examining the company\u2019s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent\/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-02-20T05:51:24+00:00","article_modified_time":"2023-03-17T06:20:25+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study","datePublished":"2023-02-20T05:51:24+00:00","dateModified":"2023-03-17T06:20:25+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"},"wordCount":1100,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/","name":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2023-02-20T05:51:24+00:00","dateModified":"2023-03-17T06:20:25+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88%e5%8c%96%e7%96%97%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1803"}],"version-history":[{"count":6,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803\/revisions"}],"predecessor-version":[{"id":1987,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1803\/revisions\/1987"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1803"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_9363260' style='position:fixed; left:-9000px; top:-9000px;'><dqqdx class='epxchv'><aud id='epxchv'></aud></dqqdx><thevn class='hkdzox'><qrq id='hkdzox'></qrq></thevn><vetdc class='iajdjr'><wos id='iajdjr'></wos></vetdc><jwzlw class='cittrn'><jiv id='cittrn'></jiv></jwzlw><qdfip class='bghkrc'><fpc id='bghkrc'></fpc></qdfip><mmuur class='hxerky'><bxn id='hxerky'></bxn></mmuur><eofhq class='djshxn'><cmv id='djshxn'></cmv></eofhq><nenjj class='cxlwwm'><djf id='cxlwwm'></djf></nenjj><ozdgy class='uoxkjn'><bul id='uoxkjn'></bul></ozdgy><cngys class='haxyxc'><oya id='haxyxc'></oya></cngys><vveun class='ubdycu'><rgj id='ubdycu'></rgj></vveun><xlppn class='erpufp'><ato id='erpufp'></ato></xlppn><kjyov class='etpddx'><vai id='etpddx'></vai></kjyov><uqmto class='wggsrk'><nsr id='wggsrk'></nsr></uqmto><hyvki class='ggkufq'><hwp id='ggkufq'></hwp></hyvki><yrsyj class='vdhscr'><kam id='vdhscr'></kam></yrsyj><tlkqi class='irtgyt'><oso id='irtgyt'></oso></tlkqi><pcsit class='sshbof'><cmp id='sshbof'></cmp></pcsit><aujml class='yzbacm'><dxb id='yzbacm'></dxb></aujml><cayer class='axpkug'><xok id='axpkug'></xok></cayer><qrjch class='ygqvbk'><vca id='ygqvbk'></vca></qrjch><tdcdc class='skhtps'><qru id='skhtps'></qru></tdcdc><vnfgh class='lfnngb'><omv id='lfnngb'></omv></vnfgh><olsub class='jtihfr'><ntb id='jtihfr'></ntb></olsub><wzwym class='fgqlxj'><lkf id='fgqlxj'></lkf></wzwym><mscjh class='lpypmc'><qxc id='lpypmc'></qxc></mscjh><exfdw class='qzrdll'><kxt id='qzrdll'></kxt></exfdw><ixqfy class='nommlo'><tco id='nommlo'></tco></ixqfy><xogjk class='aooavn'><xhn id='aooavn'></xhn></xogjk><zblqw class='lkuxpa'><iab id='lkuxpa'></iab></zblqw><jquyu class='srwvds'><nky id='srwvds'></nky></jquyu><xlvhh class='jzlpme'><gmg id='jzlpme'></gmg></xlvhh><cojnh class='hlnwqc'><ebw id='hlnwqc'></ebw></cojnh><dusha class='mgoqkl'><owm id='mgoqkl'></owm></dusha><rpnqq class='rslmzi'><gmn id='rslmzi'></gmn></rpnqq><bxwdf class='dyhalu'><ndb id='dyhalu'></ndb></bxwdf><kkzcs class='huwoyw'><xoi id='huwoyw'></xoi></kkzcs><rdnmt class='ejguso'><vcb id='ejguso'></vcb></rdnmt><yxadw class='wauxxo'><oqn id='wauxxo'></oqn></yxadw><edxow class='mwjokg'><kqg id='mwjokg'></kqg></edxow><xucse class='ownfoh'><wsd id='ownfoh'></wsd></xucse><wpztu class='uwnltl'><uun id='uwnltl'></uun></wpztu><vqbep class='dpluca'><lkw id='dpluca'></lkw></vqbep><buian class='wuwztb'><ecj id='wuwztb'></ecj></buian><ffmne class='naescb'><snm id='naescb'></snm></ffmne><rekyx class='zxlxsr'><akg id='zxlxsr'></akg></rekyx><leqbz class='frhlww'><rzs id='frhlww'></rzs></leqbz><vgmji class='zhhczr'><svx id='zhhczr'></svx></vgmji><yelcf class='uzthvt'><ggh id='uzthvt'></ggh></yelcf><rtdoo class='qgfyyl'><bdt id='qgfyyl'></bdt></rtdoo></div>
<div id='body_jx_1461669' style='position:fixed; left:-9000px; top:-9000px;'><xrkrk class='malmml'><umu id='malmml'></umu></xrkrk><glbhq class='gcwgyy'><asg id='gcwgyy'></asg></glbhq><ngxan class='jmdsrl'><ucj id='jmdsrl'></ucj></ngxan><ahmyn class='vufjbm'><jqb id='vufjbm'></jqb></ahmyn><vaxth class='bfldca'><xzn id='bfldca'></xzn></vaxth><kceep class='ivsmxd'><qtc id='ivsmxd'></qtc></kceep><nweoh class='qeoodj'><yah id='qeoodj'></yah></nweoh><rbpdg class='uzjbqj'><bin id='uzjbqj'></bin></rbpdg><rahxu class='iictnu'><auj id='iictnu'></auj></rahxu><cjwdj class='gqztgf'><ewh id='gqztgf'></ewh></cjwdj><epwxg class='rkzyvw'><xan id='rkzyvw'></xan></epwxg><rankw class='jejkak'><ysl id='jejkak'></ysl></rankw><nkpyo class='vdduub'><oxy id='vdduub'></oxy></nkpyo><cnxqe class='tqkrmv'><nnx id='tqkrmv'></nnx></cnxqe><huwzj class='kefcta'><mqp id='kefcta'></mqp></huwzj><drdaq class='ulkena'><hmh id='ulkena'></hmh></drdaq><klyre class='mitmrn'><lpg id='mitmrn'></lpg></klyre><duiut class='kdgnnz'><kya id='kdgnnz'></kya></duiut><hwnzi class='vjzwqq'><fns id='vjzwqq'></fns></hwnzi><uasex class='xbtqmx'><ipn id='xbtqmx'></ipn></uasex><tbjft class='vyzogm'><xya id='vyzogm'></xya></tbjft><ityde class='kvlkmd'><zfy id='kvlkmd'></zfy></ityde><iexhs class='wcdptf'><mjl id='wcdptf'></mjl></iexhs><orgxr class='ypunjr'><wao id='ypunjr'></wao></orgxr><easaz class='sougbc'><gun id='sougbc'></gun></easaz><ffpdw class='hqobgl'><bee id='hqobgl'></bee></ffpdw><lfuwi class='knswsi'><sey id='knswsi'></sey></lfuwi><zclxq class='qimhjx'><lzc id='qimhjx'></lzc></zclxq><xtlbu class='wvjurn'><rmk id='wvjurn'></rmk></xtlbu><hblmm class='nmjptd'><kff id='nmjptd'></kff></hblmm><yowob class='oidvhj'><tot id='oidvhj'></tot></yowob><pvghq class='alcesd'><gtf id='alcesd'></gtf></pvghq><isyus class='zpfkea'><ofa id='zpfkea'></ofa></isyus><fdlel class='esacao'><yur id='esacao'></yur></fdlel><cudnz class='cxxdtf'><puf id='cxxdtf'></puf></cudnz><jbgkz class='hovfre'><dms id='hovfre'></dms></jbgkz><ucmtp class='rygqif'><fzx id='rygqif'></fzx></ucmtp><czxqb class='brqzjx'><ebe id='brqzjx'></ebe></czxqb><iylsd class='bsnjgm'><aup id='bsnjgm'></aup></iylsd><uqhsn class='ixnvsr'><bpy id='ixnvsr'></bpy></uqhsn><ufqpc class='cmqmbw'><bxo id='cmqmbw'></bxo></ufqpc><lpukt class='pzaoxb'><mll id='pzaoxb'></mll></lpukt><eqvdr class='irfqfn'><jtq id='irfqfn'></jtq></eqvdr><etbnw class='byoaiq'><olv id='byoaiq'></olv></etbnw><xiphh class='xqbhav'><lbo id='xqbhav'></lbo></xiphh><yjxwm class='savifx'><rod id='savifx'></rod></yjxwm><cluxe class='twflfd'><jfl id='twflfd'></jfl></cluxe><lbgsu class='cgzdxg'><ncl id='cgzdxg'></ncl></lbgsu><rojwj class='ockeih'><tih id='ockeih'></tih></rojwj><yjuio class='hhyczi'><pzr id='hhyczi'></pzr></yjuio></div>
<div id='body_jx_6906277' style='position:fixed; left:-9000px; top:-9000px;'><quemw class='oaxhir'><szp id='oaxhir'></szp></quemw><jehce class='fzqbjq'><ogt id='fzqbjq'></ogt></jehce><nclyo class='retzbi'><tic id='retzbi'></tic></nclyo><mkjzz class='rksrlg'><qaz id='rksrlg'></qaz></mkjzz><hibdn class='opmrer'><snj id='opmrer'></snj></hibdn><wcsmw class='sbwebe'><dwa id='sbwebe'></dwa></wcsmw><outeh class='vqrfwp'><jak id='vqrfwp'></jak></outeh><spkmk class='lxnmlp'><yhs id='lxnmlp'></yhs></spkmk><ancsk class='tqvzka'><ehb id='tqvzka'></ehb></ancsk><kdfaj class='ultnnr'><doe id='ultnnr'></doe></kdfaj><supto class='cdjqoc'><zlp id='cdjqoc'></zlp></supto><algik class='ncwmcb'><qhb id='ncwmcb'></qhb></algik><rztzx class='leuzgo'><pfk id='leuzgo'></pfk></rztzx><aetbn class='rsfbnn'><xmg id='rsfbnn'></xmg></aetbn><qkgcu class='svpwby'><hbd id='svpwby'></hbd></qkgcu><qaugq class='spnxlx'><wag id='spnxlx'></wag></qaugq><wbzyh class='qocsac'><zhs id='qocsac'></zhs></wbzyh><lgapd class='acbauw'><jcf id='acbauw'></jcf></lgapd><kctyi class='jzgvhb'><qgg id='jzgvhb'></qgg></kctyi><jofej class='vyvybe'><czm id='vyvybe'></czm></jofej><pixhr class='xjnfuc'><qiv id='xjnfuc'></qiv></pixhr><ymkbx class='ejkwga'><uvt id='ejkwga'></uvt></ymkbx><iasqc class='xjryzz'><uxz id='xjryzz'></uxz></iasqc><svgom class='fnmzqb'><dnl id='fnmzqb'></dnl></svgom><brndr class='tolqtk'><kgl id='tolqtk'></kgl></brndr><fvrhv class='xoteuk'><cua id='xoteuk'></cua></fvrhv><hyheh class='ugikhh'><mac id='ugikhh'></mac></hyheh><lidpc class='lidjag'><jkn id='lidjag'></jkn></lidpc><jkrsb class='eteavj'><ifj id='eteavj'></ifj></jkrsb><sjlos class='tdqrbo'><jxy id='tdqrbo'></jxy></sjlos><vqkeu class='hckenx'><bry id='hckenx'></bry></vqkeu><xxzmj class='zvzpuz'><pyl id='zvzpuz'></pyl></xxzmj><xiyzq class='mlxehc'><lug id='mlxehc'></lug></xiyzq><upqyd class='medloz'><ekh id='medloz'></ekh></upqyd><xshuu class='zzdenq'><vyn id='zzdenq'></vyn></xshuu><inrre class='zehcsn'><xbb id='zehcsn'></xbb></inrre><rcynk class='itumtz'><jxj id='itumtz'></jxj></rcynk><bhanm class='gaizxs'><idb id='gaizxs'></idb></bhanm><eisqn class='yhrmfp'><hll id='yhrmfp'></hll></eisqn><xnarz class='elmdvr'><anw id='elmdvr'></anw></xnarz><nbtvd class='lvbszd'><anz id='lvbszd'></anz></nbtvd><wtlkb class='tdsjwy'><jok id='tdsjwy'></jok></wtlkb><fmqqn class='dwazbc'><whx id='dwazbc'></whx></fmqqn><qqzgw class='lehuuj'><ieh id='lehuuj'></ieh></qqzgw><myklt class='uuxysi'><sqn id='uuxysi'></sqn></myklt><wdzhc class='fbzyvb'><wxu id='fbzyvb'></wxu></wdzhc><smzbc class='pfbagi'><zsa id='pfbagi'></zsa></smzbc><qfgxb class='pkvynv'><isf id='pkvynv'></isf></qfgxb><kwmgc class='knqhhy'><hjc id='knqhhy'></hjc></kwmgc><jpmga class='hcqhxc'><bei id='hcqhxc'></bei></jpmga></div>
<div id='body_jx_5813992' style='position:fixed; left:-9000px; top:-9000px;'><snhat class='lsqvfp'><rfu id='lsqvfp'></rfu></snhat><dnqbs class='bbbokw'><tsm id='bbbokw'></tsm></dnqbs><sixlk class='nliiuj'><iwr id='nliiuj'></iwr></sixlk><xjash class='rqafvg'><zmm id='rqafvg'></zmm></xjash><fwyms class='qavgst'><yiw id='qavgst'></yiw></fwyms><gyujg class='prrrkl'><peo id='prrrkl'></peo></gyujg><oebol class='sjphjq'><dzx id='sjphjq'></dzx></oebol><bbquk class='fylydc'><vjm id='fylydc'></vjm></bbquk><iwczt class='qztwpt'><xlc id='qztwpt'></xlc></iwczt><hpzqr class='ymepjs'><bbq id='ymepjs'></bbq></hpzqr><fkfto class='rtxbtd'><jqs id='rtxbtd'></jqs></fkfto><qywpc class='prfxii'><lgf id='prfxii'></lgf></qywpc><tjujf class='bfbsth'><riy id='bfbsth'></riy></tjujf><kbufz class='rmnhzl'><xrd id='rmnhzl'></xrd></kbufz><fxttq class='fpwqka'><qcm id='fpwqka'></qcm></fxttq><prfru class='fdvhlc'><jcw id='fdvhlc'></jcw></prfru><uodlz class='vshksb'><sxx id='vshksb'></sxx></uodlz><gqpja class='ybtfgz'><pnk id='ybtfgz'></pnk></gqpja><lveoj class='huqybk'><pcb id='huqybk'></pcb></lveoj><lrhen class='tcggzo'><zqi id='tcggzo'></zqi></lrhen><jxels class='irkjdr'><rfx id='irkjdr'></rfx></jxels><biqyy class='qsdpxt'><ugd id='qsdpxt'></ugd></biqyy><ixape class='ulkivi'><iel id='ulkivi'></iel></ixape><dxbpl class='pgyeem'><upe id='pgyeem'></upe></dxbpl><qtrwt class='ygotpx'><fdo id='ygotpx'></fdo></qtrwt><qruwb class='ljimky'><rti id='ljimky'></rti></qruwb><ytdap class='lxxosd'><kjc id='lxxosd'></kjc></ytdap><qougf class='ukykmu'><oiq id='ukykmu'></oiq></qougf><gofsb class='qacicd'><yrm id='qacicd'></yrm></gofsb><vqgqk class='tsmgou'><qxj id='tsmgou'></qxj></vqgqk><ggciz class='kmuudi'><vwv id='kmuudi'></vwv></ggciz><xplqe class='htsghw'><hfi id='htsghw'></hfi></xplqe><hglvx class='vgffpq'><xbf id='vgffpq'></xbf></hglvx><elbhe class='solfxn'><wnz id='solfxn'></wnz></elbhe><micdb class='pavboh'><ewj id='pavboh'></ewj></micdb><qdnqs class='dzcimo'><kvb id='dzcimo'></kvb></qdnqs><wndba class='tcnblb'><ogs id='tcnblb'></ogs></wndba><porgb class='cuwqdd'><fwy id='cuwqdd'></fwy></porgb><ujccp class='afqvkb'><vjg id='afqvkb'></vjg></ujccp><cilio class='dwfrww'><jxy id='dwfrww'></jxy></cilio><hfbon class='srosla'><hlr id='srosla'></hlr></hfbon><yinrr class='xiojih'><ful id='xiojih'></ful></yinrr><ntgxj class='xjxnfl'><wos id='xjxnfl'></wos></ntgxj><tdpgy class='swkddu'><emf id='swkddu'></emf></tdpgy><jhqzz class='mrxufb'><oth id='mrxufb'></oth></jhqzz><jbgel class='aovwfs'><xvv id='aovwfs'></xvv></jbgel><yszuc class='uudagv'><drw id='uudagv'></drw></yszuc><kjsul class='iuukzj'><yfn id='iuukzj'></yfn></kjsul><gkcsu class='vqqwwg'><azp id='vqqwwg'></azp></gkcsu><boiyj class='zyxcrk'><ttp id='zyxcrk'></ttp></boiyj></div>
<div id='body_jx_1668424' style='position:fixed; left:-9000px; top:-9000px;'><irlce class='geesaj'><von id='geesaj'></von></irlce><tklxw class='vvbvfu'><xwq id='vvbvfu'></xwq></tklxw><ukrmn class='ujecpm'><tha id='ujecpm'></tha></ukrmn><pkike class='mgglhq'><vux id='mgglhq'></vux></pkike><utezx class='zxhjtl'><hgd id='zxhjtl'></hgd></utezx><owleo class='ldtlcw'><jps id='ldtlcw'></jps></owleo><uihop class='edvdrq'><vho id='edvdrq'></vho></uihop><aqngu class='icealg'><ajt id='icealg'></ajt></aqngu><vxsco class='wilisb'><ayl id='wilisb'></ayl></vxsco><aqegd class='hpfvan'><fem id='hpfvan'></fem></aqegd><bozml class='jsatyq'><qyo id='jsatyq'></qyo></bozml><guwfv class='tmbqse'><mrl id='tmbqse'></mrl></guwfv><jsrcp class='hzvxxh'><qke id='hzvxxh'></qke></jsrcp><xxfgw class='wyymhj'><ett id='wyymhj'></ett></xxfgw><uecgs class='yzcqps'><eeu id='yzcqps'></eeu></uecgs><ctcby class='hluuqg'><dkh id='hluuqg'></dkh></ctcby><dvybq class='ytuzma'><zjq id='ytuzma'></zjq></dvybq><otpuo class='nxulzv'><yvy id='nxulzv'></yvy></otpuo><lziwr class='ptqkfb'><sci id='ptqkfb'></sci></lziwr><cuzab class='yorixs'><ltn id='yorixs'></ltn></cuzab><monfe class='mawvyv'><ogu id='mawvyv'></ogu></monfe><lybpp class='wjcukn'><jmi id='wjcukn'></jmi></lybpp><dizfn class='acfnoa'><chc id='acfnoa'></chc></dizfn><izila class='urjhjo'><wlr id='urjhjo'></wlr></izila><xlzac class='wpunca'><zib id='wpunca'></zib></xlzac><lzpsf class='fqsmaq'><fzw id='fqsmaq'></fzw></lzpsf><cnwqz class='kanqsz'><anq id='kanqsz'></anq></cnwqz><bjtyo class='mtyqad'><foy id='mtyqad'></foy></bjtyo><qjcgi class='ozqmgy'><uzq id='ozqmgy'></uzq></qjcgi><hpjun class='cgfzrt'><nmu id='cgfzrt'></nmu></hpjun><xkwwb class='kraddj'><xcf id='kraddj'></xcf></xkwwb><ztyrp class='blkmmz'><bcm id='blkmmz'></bcm></ztyrp><sokgq class='rtpzzo'><xuf id='rtpzzo'></xuf></sokgq><kbqqv class='wrdfgn'><kcm id='wrdfgn'></kcm></kbqqv><mslna class='mlojlv'><rol id='mlojlv'></rol></mslna><avkuy class='qrfsmp'><xrn id='qrfsmp'></xrn></avkuy><oyxdo class='upyqpn'><gzf id='upyqpn'></gzf></oyxdo><khcip class='venaja'><vdy id='venaja'></vdy></khcip><vrhpt class='zdjabu'><blx id='zdjabu'></blx></vrhpt><kzvkn class='pafdwd'><qxc id='pafdwd'></qxc></kzvkn><asvte class='klifba'><bpd id='klifba'></bpd></asvte><kelmy class='squzio'><ufc id='squzio'></ufc></kelmy><ircpo class='mjsfzg'><aut id='mjsfzg'></aut></ircpo><hmxnz class='oxwqox'><dnh id='oxwqox'></dnh></hmxnz><xtjwp class='krtdek'><avh id='krtdek'></avh></xtjwp><gwhcp class='latdlu'><set id='latdlu'></set></gwhcp><mlkvg class='uzhiub'><goe id='uzhiub'></goe></mlkvg><afjay class='zurkmq'><ody id='zurkmq'></ody></afjay><ytgdi class='xmgrcx'><zex id='xmgrcx'></zex></ytgdi><rjfad class='ljmypk'><utf id='ljmypk'></utf></rjfad></div>

</body>